Sonoma PHARMACEUTICALS
A Relentless Passion For Healing

STONEGATE CAPITAL PARTNERS

2/27/18

Laura S. Engel, CPA
laura@stonegateinc.com
214-987-4121

MARKET STATISTICS

Exchange / Symbol	NASDAQ: SNOA
Price:	$4.22
Market Cap ($mm):	$20.0
Enterprise Value ($mm):	$11.7
Shares Outstanding (mm):	4.7
Float (%):	94%
Volume (3 month avg.):	30,000
52 Week Range:	$4.05-$8.25
Industry:	Specialty Pharmaceuticals

CONDENSED BALANCE SHEET

($mm, except per share data)

Balance Sheet Date:	12/31/2017
Cash & Cash Equivalent:	$8.63
Cash/Share:	$1.82
Equity (Book Value):	$14.26
Equity/Share:	$3.01

CONDENSED INCOME STATEMENTS

($mm, except per share data)

FY - 03/31	Revenue	Net Income	Adj. EBITDA	EPS
FY16	$9.4	$(10.2)	$(12.4)	$(3.09)
FY17*	$12.8	$9.3	$(10.5)	$2.17
FY18E	$17.3	$(12.9)	$(10.2)	$(2.87)
FY19E	$20.0	$(8.8)	$(6.2)	$(1.70)

*Includes discontinued operations

LARGEST SHAREHOLDERS

Bard Associates, Inc.	334,200
The Vanguard Group, Inc.	86,200
Renaissance Technologies Corp.	58,600
JW Asset Management, LLC	41,000
BlackRock, Inc.	28,700
Deutsche Bank	25,100
National Asset Management, Inc.	14,800
Geode Capital Management, LLC	13,200
Aurus S.A.	12,000
GW & Wade, LLC	11,000

STOCK CHART



COMPANY DESCRIPTION

Sonoma Pharmaceuticals, Inc. (Sonoma) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care based upon its proprietary technology Microcyn®. The Company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itching, pain, scarring, and harmful inflammatory responses. The Company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

SUMMARY

As part of this notable turnaround story, Sonoma Pharmaceuticals continues to expand domestically and abroad, capturing greater share of the US dermatology market and executing upon its revamped long-term strategic plan put in place mid-2014.

- As of 12/6/16, the Company announced a name change from Oculus Innovative Sciences, Inc. to Sonoma Pharmaceuticals, Inc. as part of a rebranding initiative and the Company's commitment to focusing on the high-margin US dermatology market moving forward.
- The dermatology market offers tremendous upside potential. Within dermatology, the Company has a core focus of topical dermatitis, a $1.3B addressable market, and a secondary focus of systemic acne, a $3.9B addressable market. Also, Sonoma has launched a new scar treatment to support the approximately 42 million surgical skin procedures that are performed in the US per year, with many patients experiencing hypertrophic scarring and keloids after those surgical procedures; newer product launches address sizable markets as well.
- Sonoma currently sells six product lines in the US, with some products developed in-house and some acquired, and the Company has several additional products set to hit the market 2018.
- Sonoma created a new direct sales force in 2014 with 14 sales team members initially. Currently, the Company has a sales team of 30 sales reps and 5 senior sales managers, both to support the launch of products and to increase market share for those currently in the bags.
- The Company's Microcyn®-based products are sold throughout the US and the world and have treated more than 5M patients globally to reduce infection, itch, pain, scarring, and harmful inflammatory responses; these products are based on technology designed to be a non-irritating, shelf-stable solution containing oxychlorine compound with an established safety profile.
- The Company grows sales abroad through its relationships with distributors. Approximately 38% of its revenue came from sales internationally in Q3 FY18. Sonoma has made a concerted effort to engage strong partners internationally.
- As of 10/31/16, management announced the sale of its Latin American business for $19.5M cash to Invekra S.A.P.I. de C.V of Mexico; the deal enabled the Company to sell a slower growing, lower margin segment of its business in exchange for a sizable cash payment that has been put to work advancing its US dermatology business (fast growing and higher margin).
- A key focus for management is driving towards EBITDA breakeven; management has stated that this goal is achievable with an annualized run rate of ~$26M (current annualized revenue run rate ~$19M) and 30 – 34 sales reps (currently 30).
- As of 12/31/17, the Company reported $4.8M in total revenue for Q3 FY18, the highest quarterly revenue for SNOA ever, driven by growth in US dermatology as prescriptions units shipped continue to climb, with over 19,000 in the quarter, and with approximately $8.6M in cash on hand and minimal debt.

On an EV/R basis, Sonoma currently trades at 0.6x vs. the median of its peers at 3.0x based on FY19 estimates. In addition, companies in the dermatology space have been acquired at a median EV/R multiple of 3.6x. See pages 9 – 10 for further details.

MICROCYN® TECHNOLOGY

The Company's principal technology platform Microcyn® is a potent broad-spectrum antimicrobial designed to treat a wide range of pathogens, including viruses, fungi, spores and antibiotic-resistant strains of bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE), and Clostridium difficile, among others. All of these cause disease or inhibit the healing in both acute and chronic wounds. Microcyn® products are generated through a unique, patented electrochemical treatment of diluted saltwater where a pH neutral solution of hypochlorous acid, and its sodium salt, hypochlorite, is generated. The hypochlorous acid in Microcyn®, similar to the natural hypochlorous acid produced by the human body, preserves the Microcyn® solution. In addition, Microcyn® has demonstrated a reduction in inflammation, itch, pain, skin infections, healing and scarring without irritation and side effects.

Microcyn® is a non-irritating, shelf-stable solution containing an oxychlorine compound. Its safety profile has been established as comparable to saline through treatment of over five million patients to date, and efficacy and safety have been validated via more than 30 clinical studies. There are several unique qualities that set Microcyn® apart from other technologies in the dermatology and wound care markets. Its advantages include:

- Microcyn® is based on shelf-stable hypochlorous acid – Hypochlorous acid (HOCI) is unquestionably a potent sterilization agent. The human immune system manufactures it to kill harmful microbes. There are other companies in these markets that produce HOCI formulations; however, these formulations typically become unstable after a short time.
- Microcyn® has multiple applications – Microcyn® has been proven in laboratory studies to kill fungus, spores, viruses, and bacteria, including antibiotic-resistant bacteria such as MRSA, VRE and Pseudomonas in just 30 seconds. With the proliferation of "super bug" mutations reaching a high level, there is clearly a need for an effective broad spectrum antimicrobial. Additionally, Microcyn® based products have proven therapeutic capabilities to relieve various irritations and afflictions of the skin and improve the healing process.
- It has a strong safety profile – Microcyn®'s safety profile has been established through the treatment of over five million patients to date under FDA 510(k) clearances as a medical device in the United States, and its efficacy has been validated through more than 30 clinical studies. Microcyn® has received the European Union certification for wound cleaning, reduction of microbial load, treatment of acne, atopic dermatitis and scar management, among others, as well as various drug approvals in Mexico, Latin America, the Caribbean, India, China, as well as other Asian countries and throughout the Middle East.
- There is low potential for resistance – Because Microcyn® does not target specific strains of bacteria, which tends to promote resistance, there is a very low potential for the bacteria to develop resistance against this treatment formulation.
- Microcyn® line is well suited for the dermatology market – The Company is primarily targeting the dermatology market, which benefits from having shorter development time, lower clinical trial costs and regulatory hurdles, and offers a level of pricing power. In addition, Microcyn® has demonstrated a reduction in inflammation, itch, pain, skin infections, healing and scarring without irritation and side effects related to many competitive, steroid-based products.

Exhibit 1: Sonoma Products Offerings Developed In-house

Source: Company Reports

As last reported, the Company had a total of 63 issued patents, with 33 applications pending in the US and abroad. Patent claims cover:

- Chemical composition
- Apparatus
- Method of manufacturing
- Therapeutic uses

DERMATOLOGY PRODUCTS

Sonoma currently has 6 dermatology product lines being sold in the US and has announced additional approvals for products in the US and abroad. Most recently the Loyon® skin descaling product was approved by the FDA and launched October 2017. Management has the stated goal of launching several new products in the upcoming six months to one year. Below we review two of the more established product lines, Levicyn™ (previously Alevicyn™) and Celacyn™.

The Company received FDA clearance for **Levicyn™ Antipruritic Gel** in March 2010, and it was approved for the use of managing atopic and radiation dermatitis in February 2011, with a US patent issued for atopic dermatitis. Levicyn™ is intended to reduce or replace the use of corticosteroids. **Levicyn™ Dermal Spray** for reduction of pain and itch in skin dermatoses was introduced November 2014, followed by **Levicyn™ Spray Gel** for trunk dermatitis in early 2015. Just recently, both the dermal spray and gel products received approval from the FDA for expanded language to include antimicrobial claims.

The Company estimates the addressable US market for the Levicyn™ products at approximately $500 - $600 million. Pricing has been established around ~$220 (170 grams) with up to a $60 rebate; a comparable course of corticosteroids can cost in the $100 - $800 range.

Exhibit 2: Atopic Dermatitis Product Comparison

	Topical Immunomodulators	Topical Corticosteroids	Levicyn
Reduces Itch	Very Good	Very Good	Very Good
Reduces Inflammation	Very Good	Very Good	Good
Anti-microbial & Time to Kill	Neutral	Neutral	Very Good
Improves Broken Skin	Very Poor	Very Poor	Very Good
Safety	Very Poor	Very Poor	Very Good
Side Effects	Very Poor	Very Poor	Very Good

Source: Company Reports, Stonegate Capital Partners

Additionally, Sonoma faces other competitive products in this area such as Novartis' Elidel® Cream and Astellas' Protopic®, both prescription medicines addressing moderate to severe eczema, or atopic dermatitis.

Celacyn™ Scar Management Gel prescription treatment was introduced in early 2015. It is one of only two approved prescription scar products in the US. It is approved for the management of old and new keloid and hypertrophic scarring.

The Company estimates that the addressable US market includes approximately 62 million new scars formed annually, and clinical study results have demonstrated Celacyn™ advantages over the competition.

Exhibit 3: Percentage of Improvement Over Baseline at 12 Weeks – Celacyn vs. Kelo-Cote in Double Blind, Randomized Clinical Study



Source: Company Reports

GROWTH STRATEGY

Since mid-2014, Sonoma has been executing upon a new strategic plan put in place to more keenly focus its target markets and to drive the top line. As part of its new long-term plan, the Company spun off its surgical products division and recently sold its Latin American business, brought in new management as well as directors, made a decision to go after the dermatology market with full force, and executed a name change. Funds from the spin-off of its surgical products division were utilized to kick start the process. Management has set out the following approach to reaching Sonoma's long-term goals.

Establish a Direct Sales Platform in the US Focused on Derm: In fall 2014, the Company deployed a direct salesforce in the US, using Microcyn® as its cornerstone technology, and subsequently launched several new products under its new IntraDerm Pharmaceuticals division. The Sonoma sales team is made up of seasoned sales veterans that have established relationships with dermatologists, and many of those are heavy prescription writers. As last reported, the Company had a salesforce of 35, with the average salesperson having 10.3 years experience in dermatology. We note that 13 of these sales reps were hired near the end of March 2017 quarter, which should continue the quick ramp in the top line in the near-term.

Continue Strong Sales Abroad via International Distribution Network: The Company maintains an international network of distributors in over 30 countries to support and grow sales abroad. In Europe and the rest of the world, Sonoma continues to support and build out a network of international distributors for its broad portfolio of CE Mark and other international approvals. As of October 31, 2016, Sonoma announced the sale of its Latin American business to Invekra for $19.5M in cash; additionally, Invekra will pay the Company a 3% royalty going forward on all Latin American revenues outside of Mexico, with a minimum of $250K per year for the next 10 years. While Sonoma sold all its Latin American assets related to Microdacyn-based products sold there and in the Caribbean, the Company maintains rights to dermatology products sales in Brazil and in October 2017 received multiple approvals to market its hypochlorous acid-based

dermatology products; SNOA is currently seeking a Brazilian healthcare company partner to license these newly approved products for sale in the Brazilian derm space.

Notably, the Company will maintain its current manufacturing facility in Mexico for production of its Sonoma-branded Microdacyn-based products for all countries outside of the US and Latin America. Overall, the deal with Invekra allowed the Company to sell a slower growing, lower margin segment of its business in exchange for a sizable cash payment that can be put to work advancing its US dermatology business (fast growing and higher margin).

Create a Competitive Pricing Strategy: Sonoma has a unique product pricing strategy, which it believes bridges many of the challenges associated with the prescription dermatology market's pricing and rebate programs. The Company recently increased dermatology product prices, which has had a very positive impact on operations to date. Expectations are for a 10% - 20% increase in dermatology products prices overall in 2018.

Develop a Pharmaceutical Line: The Company plans to acquire and/or develop pharmaceutical products with affordable clinical trials to increase its market presence and will protect its proprietary technology with innovator patent protection. Fairly recently, the Company licensed and launched Mondoxyne, an oral drug approved for the treatment of severe acne, which is a bestseller by dollars for Sonoma. Additionally, Sonoma end-licensed Ceramax™ with FDA approval for atopic dermatitis and launched sales in April 2016 (noted as the fastest growing product for Q3 FY18); the Company also launched Lasercyn™ in August 2016 for the treatment of post laser and microdermabrasion procedures as well as chemical peels. In Q3 FY17, the Company launched SebuDerm for the treatment of seborrhea dermatitis. Most recently, Sonoma received FDA clearance for Loyon® Skin Descaler, which launched fall 2017.

Exhibit 4: Acquired Product Lines

Source: Company Reports

Re-establish Presence in Animal Healthcare Market with New Partner: The Company recently launched two new products for animals – MicrocynAH® Anti-Itch Spray Gel and MicrocynAH® Hot Spot Spray Gel. Sonoma established the MicrocynAH family of animal healthcare products for North America in February of 2015 and has partnered with Manna Pro Products for distribution in the US. In February 2017, Sonoma announced that PetSmart, Inc. had launched the MicrocynAH® family of healthcare products with chain-wide availability at 1,500+ stores across North America. In September 2017, SNOA commercialized its first MicrocynAH® animal healthcare products in Japan.

Through careful execution of its growth strategy, Sonoma should be capable of generating continued increases in prescriptions quarter-over-quarter, reaching one the Company's most important milestones of EBITDA breakeven; management has stated that this goal is achievable with an annualized run rate of ~$26M (current annualized revenue run rate is ~$19M) and 30 – 34 sales reps.

GLOBAL SNAPSHOT

The Company expects to grow its product revenues in the US and abroad in FY18 and beyond, with the US becoming a larger part of that mix within the short-term.

Exhibit 5: Product Revenues for Quarter ending 12/31/17



Source: Company Reports, Stonegate Capital Partners

United States: Sonoma is focused primarily on the dermatology market and secondarily on advanced wound tissue care. As mentioned, management has the stated goal of launching several new products in the upcoming six months to one year utilizing its own salesforce. Meanwhile, the Company's acute care team continues to advance market adoption of the Microcyn® tissue care products. Partner Manna Pro Products, LLC will handle sales and distribution of animal healthcare products, principally marketing non-prescription animal care products for pet, equine and farm animal to venues in the US and Canada.

Europe: Sonoma currently has distribution partners in Austria, Belgium, Italy, Liechtenstein, Luxemburg, the Netherlands, Germany, Greece, the Czech Republic, Sweden, Spain, Norway, Switzerland, Poland, Finland, Denmark and Serbia.

Latin America: As of 10/31/16 the Company announced the sale of its Latin American business for $19.5M in cash as well as 10-year annual payment of 3% on Latin American sales, excluding Mexico, with a minimum of $250,000 per year. Sonoma retains rights to sell dermatology products in Brazil and is currently seeking a partner to license approved products.

Rest of World: Strategic partnership have been formed for sales and distribution of Microcyn®-based products in Bangladesh, Pakistan, India, China, UAE, Saudi Arabia, Dubai, Kuwait, Iraq, Singapore, Indonesia, Malaysia, Australia and New Zealand.

DERMATOLOGY MARKET

The dermatology market is large and can offer certain pricing flexibility not afforded by other areas of healthcare. This highly competitive marketplace is characterized by an often affluent patient base willing to pay out of pocket. Management is looking to capitalize on the potential of capturing a meaningful segment of the market with a smaller salesforce, given that it's frequently a concentrated group of dermatologists writing the bulk of prescriptions.

Exhibit 6: Potential Dermatology Indications & Annual Topical Total Prescriptions

Core Focus:	
Topical Dermatitis	
	6.9M 2016 prescriptions
	$1.3B addressable market
Secondary Focus:	
Systemic Acne	
	7.0M 2016 prescriptions
	$3.9B addressable market
Future Focus:	
Topical Acne	
	8.7M 2016 prescriptions
	$1.6B addressable market

With the Company's newer strategic plan of being a pure play dermatology-focused company, Sonoma initially targeted two areas in the US: atopic dermatitis and prescription scar products. More recent approvals have been granted for a patented skin repair and seborrheic derm products. The Company also recently acquired rights to a branded acne drug.

Exhibit 7: US Breakdown of Surgical Skin Procedures



Total: 42.3MM
Source: Company Reports

Approximately 42 million surgical skin procedures are performed in the US per year based on the market survey conducted by The Nemetz Group in 2009. Moreover, 62 million scars are formed annually in the US according to the Center for Disease Control. Many patients experience hypertrophic scarring and keloids (overgrowth of scar tissues) after the surgical procedures. It is estimated that 93 million people in the US are living with scars, and about 169 million scars can be characterized as hypertrophic or keloid (raised and red colored scars due to overgrowth of repairing tissues) according to Frost & Sullivan.

RISKS

As with any investment, there are certain risks associated with Sonoma's operations as well as with the surrounding economic and regulatory environments.

- Sonoma faces operational challenges in executing its strategy. While the Company has established direct sales teams in the dermatology and advanced tissue care markets, the Company partners with distributors to market and sell its other products. If these distributors do not invest enough resources or there is a misstep in educating their teams, sales of Sonoma's products could be hampered.
- There are stringent regulatory requirements in the US and abroad where government authorities strictly regulate the research, testing, manufacturing and sales of pharmaceutical products, biologics, and medical devices. All of the Company's products require approval by government agencies prior to being commercialized, and then there are various compliance standards that must be met and/or maintained subsequent to launching a product. As last reported, the Company had seventeen 510(k) clearances from the FDA for its products to be used as medical devices, as well as numerous comparable approvals in countries abroad. Should the Company fail to meet or comply with any of these regulatory requirements, future financial results could be severely affected.
- The Company has patents issued to protect proprietary rights covering its Microcyn® technology and current know-how related to chemical composition, methods of manufacturing, and targeted indications, among others. Even if patents are issued, they can be challenged by competitors. Additionally, competitors can develop modified, non-infringing versions of the drug in order to obtain approval for sales. Litigation related to IP infringement can be lengthy and very costly to prove.
- Sonoma has a history of losses. The Company incurred a net loss for almost all the quarters in the last five years. As of Q3 FY18, Sonoma reported an accumulated deficit of approximately $152.7M. Should the Company be unable to obtain additional capital as needed at reasonable terms, the result would likely be a delay in the expansion of its product sales and pipeline, which in turn would impair the Company's ability to execute upon its long-term strategic plan to profitability.

RECENT RESULTS

On February 7, 2018, the Company announced financial results for the third quarter fiscal 2018. Below we outline year-over-year results and note certain variances. In general, quarterly performance was in-line with management's guidance.

Exhibit 8: Variation Analysis Year-over-year

Sonoma Pharmaceuticals, Inc.
Consolidated Statements of Income (in thousands $, except per share amounts)
Fiscal Year: March

	Q3 FY17	Q3 FY18	Variance	
Total revenues	**$ 3,361**	**$ 4,843**	**1,482**	Product revenues up y-o-y increase driven by strong growth in US, Europe, and Latin America
Total cost of revenues	1,655	2,475	**820**	
Gross profit (loss)	**1,706**	**2,368**		Gross margins 49% vs. 51% in PY due to lower profitability in Latin America related to Invekra offset by higher margin US derm sales
Operating expenses				
Research and development	487	349	**(138)**	Comparable y-o-y
Selling, general and administrative	4,784	5,219	**435**	Higher sales expense related to growing derm sales force
Total operating expenses	5,271	5,568		
Income (loss) from operations	**(3,565)**	**(3,200)**		
Total other income (expense)	288	13	**(275)**	Primarily related to foreign exchange losses and franchise tax payments, as well as increased interest expense related to capital leases, somewhat offset by higher interest income on cash balances
Pre-tax income (loss)	**(3,277)**	**(3,187)**		
Provision for taxes (benefit)	**4,040**	**-**	**(4,040)**	Relates to the sale of the Latin American business to Invekra
Income (loss) from continuing operations	**$ 763**	**$ (3,187)**		
Income from discontinued operations, net of tax	15,465	-	**(15,465)**	Relates to the sale of the Latin American business to Invekra
Net income (loss)	**16,228**	**(3,187)**		
Basic EPS (loss) - continuing ops	**$ 0.18**	**$ (0.73)**		
Basic EPS (loss) - discontinued ops	**$ 3.66**	**$ -**		
	$ 3.84	**$ (0.73)**		
Diluted EPS (loss) - continuing ops	**$ 0.18**	**$ (0.73)**		
Diluted EPS (loss) - discontinued ops	**$ 3.66**	**$ -**		
	$ 3.84	**$ (0.73)**		
Basic shares outstanding	4,225	4,392		
Diluted shares outstanding	4,228	4,392		

Source: Company Reports, Stonegate Capital Partners

Notably, Sonoma reported that dermatology prescription units shipped have grown 14% quarter-over-quarter on an average basis for the last 8 quarters; additionally, plans are to continue moving forward with this quick expansion of its US sales team initiatives and portfolio of dermatology products to drive the top line.

It is estimated that in order to reach profitability, SNOA needs a top line annualized run rate of ~$26M (current annualized revenue run rate is ~$19M) and 30 – 34 sales reps (currently at 30). Cash operating expenses should remain relatively flat moving forward ($4.3 to $4.6M range), and the US nonderm business, Europe and the rest of the world will grow at a relatively slow 5 – 10% pace y-o-y.

BALANCE SHEETS

Sonoma Pharmaceuticals, Inc.
Consolidated Balance Sheets (in thousands $)
Fiscal Year: March

ASSETS	FY 2016	FY 2017	Q3 FY 2018
Current Assets			
Cash and cash equivalents	7,469	17,461	8,625
Accounts receivable, net	1,508	2,108	2,609
Inventories, net	1,595	2,221	2,701
Prepaid expenses & other	1,505	616	1,508
Current portion of deferred consideration, net	-	237	229
Current assets of discontinued operations	811	-	-
Total Current Assets	**12,888**	**22,643**	**15,672**
Property and equipment, net	850	1,239	1,200
Deferred consideration, net, less current portion	-	1,497	1,392
Other assets	65	80	91
Total Assets	**$ 13,803**	**$ 25,459**	**$ 18,355**
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current Liabilities			
Accounts payable	1,337	1,255	1,400
Accrued expenses and other current liabilities	1,526	1,302	1,515
Deferred revenue	274	521	180
Deferred revenue Invekra	-	-	140
Current portion of LTD	114	123	12
Current portion of capital leases	-	74	146
Taxes payable	-	13	-
Current liabilities of discontinued operations	300	-	-
Total Current Liabilities	**3,551**	**3,288**	**3,393**
Long-Term Liabilities			
Deferred revenue Invekra	-	527	492
LTD, less current portion	-	45	35
Long-term capital leases, less current portion	-	168	179
Long-term liabilities of discontinued operations	112	-	-
Total Liabilities	**3,663**	**4,028**	**4,099**
Stockholders' Equity			
Common stock	1	1	1
Additional paid-in capital	166,368	168,709	171,332
Accumulated other comprehensive loss	(3,854)	(4,178)	(4,400)
Accumulated deficit	(152,375)	(143,101)	(152,677)
Total Stockholders' Equity	**10,140**	**21,431**	**14,256**
Total Liabilities and Stockholders' Equity	**$ 13,803**	**$ 25,459**	**$ 18,355**
Ratios			
Liquidity			
Current Ratio	3.6x	6.9x	4.6x
Quick Ratio	3.0x	6.2x	3.8x
Working Capital	$9,337	$19,355	$12,279
Leverage			
Debt To Equity	1.1%	0.8%	0.3%
Debt To Capital	1.1%	0.8%	0.3%

Source: Company Reports, Stonegate Capital Partners

INCOME STATEMENTS

Sonoma Pharmaceuticals, Inc.
Consolidated Statements of Income ($000s, except per share)
Fiscal Year: March

	FY 2016	FY 2017	FY 2018 E	FY 2019 E
Revenues				
Product and product-related	$ 8,308	$ 11,957	$ 16,487	$ 19,289
Service	1,061	868	825	750
Total revenues	**9,369**	**12,825**	**17,312**	**20,039**
Cost of revenues				
Product	5,840	6,419	7,623	7,523
Service	881	738	711	630
Total cost of revenues	6,721	7,157	8,334	8,153
Gross profit (loss)	**2,648**	**5,668**	**8,978**	**11,887**
Operating expenses				
Research and development	1,806	1,576	1,376	1,200
Selling, general and administrative	15,556	17,066	20,375	19,500
Total operating expenses	17,362	18,642	21,751	20,700
Income (loss) from operations	**(14,714)**	**(12,974)**	**(12,774)**	**(8,813)**
Other income (expense):				
Interest expense	(3)	(3)	(40)	(30)
Interest income	2	22	115	65
Change in fair value of derivative liability or stock	11	-	-	-
Tax benefit	-	4,268	-	-
Other income (expense), net	(20)	18	(179)	-
Total other income (expense)	(10)	4,305	(104)	35
Pre-tax income (loss)	**(14,724)**	**(8,669)**	**(12,878)**	**(8,778)**
Provision for taxes (benefit)	-	-	-	-
Income (loss) from continuing operations	**$ (14,724)**	**$ (8,669)**	**$ (12,878)**	**$ (8,778)**
Income from discontinued operations, net of tax	4,562	17,943	-	-
Net income (loss)	**(10,162)**	**9,274**	**(12,878)**	**(8,778)**
Basic EPS (loss) - continuing ops	**$ (4.48)**	**$ (2.03)**	**$ (2.87)**	**$ (1.70)**
Basic EPS (loss) - discontinued ops	**$ 1.39**	**$ 4.20**	**$ -**	**$ -**
	$ (3.09)	**$ 2.17**	**$ (2.87)**	**$ (1.70)**
Diluted EPS (loss) - continuing ops	**$ (4.48)**	**$ (2.03)**	**$ (2.87)**	**$ (1.70)**
Diluted EPS (loss) - discontinued ops	**$ 1.39**	**$ 4.20**	**$ -**	**$ -**
	$ (3.09)	**$ 2.17**	**$ (2.87)**	**$ (1.70)**
Basic shares outstanding*	3,289	4,270	4,485	5,158
Diluted shares outstanding*	3,289	4,270	4,485	5,158
Adjusted EBITDA	(12,447)	(10,483)	(10,224)	(6,213)
Margin Analysis				
Gross margin	28.3%	44.2%	51.9%	59.3%
Research and development	19.3%	12.3%	7.9%	6.0%
Selling, general and administrative	166.0%	133.1%	117.7%	97.3%
Operating margin	-157.0%	-101.2%	-73.8%	-44.0%
EBITDA margin	-132.9%	-81.7%	-59.1%	-31.0%
Pre-tax margin	-157.2%	-67.6%	-74.4%	-43.8%
Net income margin	-157.2%	-67.6%	-74.4%	-43.8%
Tax rate	0.0%	0.0%	0.0%	0.0%
Growth Rate Analysis Y/Y				
Total revenues	n/a	36.9%	35.0%	15.8%
Total cost of revenues	n/a	6.5%	16.4%	-2.2%
Research and development	n/a	-12.7%	-12.7%	-12.8%
Selling, general and administrative	n/a	9.7%	19.4%	-4.3%
Operating income	n/a	11.8%	1.5%	31.0%
Adjusted EBITDA	n/a	15.8%	2.5%	39.2%
Pre-tax income	n/a	41.1%	-48.5%	31.8%
Net income	n/a	41.1%	-48.5%	31.8%
EPS - fully diluted	n/a	54.7%	-41.4%	40.7%
Share count - fully diluted	n/a	29.8%	5.0%	15.0%

Source: Company Reports, Stonegate Capital Partners estimates

**Adjusted for reverse stock split June 2016 1-for-5*

VALUATION

As of mid-2014, CEO Jim Schutz described the Company's operations as "a mile wide and an inch deep." Financial results were suffering, and management was struggling to define the direction of the business. As a result, Sonoma put in place a new long-term strategic plan that included an overhaul of the management team as well as some housekeeping related to its Board of Directors. The Company decided to focus on the dermatology market going forward and to launch its own direct US salesforce. Now, having just finished Q3 FY18, Sonoma is reaping the benefits of its significant turnaround, recently reporting total revenues up ~44% for the third quarter over the same period last year, led by growth in US dermatology sales and noting that dermatology prescription units shipped have grown 14% quarter-over-quarter on an average basis for the last 8 quarters. Additionally, at 12/31/17 the Company reported approximately $8.6M in cash on hand, $12.3M in working capital, minimal debt, and an intention to launch several additional products over the upcoming year. Also, as of December 8, 2017, Sonoma put in place an ATM for up to $5M, of which ~$1M has been utilized.

Looking ahead, we believe that Sonoma has positioned itself for strong growth in the dermatology market. Per the summary comparables analysis detailed below, on an EV/R basis, SNOA trades at 0.6x vs. the median of its peers at 3.0x based on the FY19 revenue estimates.

Exhibit 9: Comparables Analysis ($mm except per share information)

Name	Ticker	Price	Sh	Mrkt Cap	EV	Revenues 2019E
AcelRx Pharmaceuticals, Inc.	ACRX	$ 1.90	50.3	$ 95.6	$ 50.1	$ 26.3
Achaogen, Inc,	AKAO	$ 11.06	42.4	$ 468.9	$ 294.5	$ 63.9
Adamis Pharmaceuticals Corp.	ADMP	$ 3.15	33.4	$ 105.2	$ 87.0	$ 61.0
Collegium Pharmaceutical, Inc.	COLL	$ 24.58	32.6	$ 801.3	$ 694.9	$ 322.1
Dermira, Inc.	DERM	$ 26.94	41.8	$ 1,126.6	$ 855.1	$ 50.3
MyoKardia, Inc.	MYOK	$ 61.10	35.7	$ 2,183.8	$ 1,936.6	$ 14.0
Paratek Pharmaceuticals, Inc.	PRTK	$ 13.70	31.1	$ 426.1	$ 311.7	$ 59.5
Tetraphase Pharmaceuticals, Inc.	TTPH	$ 2.87	51.6	$ 148.1	$ (13.3)	$ 22.2
Titan Pharmaceuticals, Inc.	TTNP	$ 1.00	21.2	$ 21.2	$ 16.2	$ 5.4
Sonoma Pharmaceuticals, Inc.*	**SNOA**	**$4.22**	**4.7**	**$ 20.0**	**$ 11.7**	**$ 20.0**

Name	Ticker	Price	Sh	Mrkt Cap	EV	EV/Revs 2019E
AcelRx Pharmaceuticals, Inc.	ACRX	$ 1.90	50.3	$ 95.6	$ 50.1	1.9x
Achaogen, Inc,	AKAO	$ 11.06	42.4	$ 468.9	$ 294.5	4.6x
Adamis Pharmaceuticals Corp.	ADMP	$ 3.15	33.4	$ 105.2	$ 87.0	1.4x
Collegium Pharmaceutical, Inc.	COLL	$ 24.58	32.6	$ 801.3	$ 694.9	2.2x
Dermira, Inc.	DERM	$ 26.94	41.8	$ 1,126.6	$ 855.1	17.0x
MyoKardia, Inc.	MYOK	$ 61.10	35.7	$ 2,183.8	$ 1,936.6	138.3x
Paratek Pharmaceuticals, Inc.	PRTK	$ 13.70	31.1	$ 426.1	$ 311.7	5.2x
Tetraphase Pharmaceuticals, Inc.	TTPH	$ 2.87	51.6	$ 148.1	$ (13.3)	-0.6x
Titan Pharmaceuticals, Inc.	TTNP	$ 1.00	21.2	$ 21.2	$ 16.2	3.0x
					Average	**19.2x**
					Median	**3.0x**
Sonoma Pharmaceuticals, Inc.*	**SNOA**	**$ 4.22**	**4.7**	**$ 20.0**	**$ 11.7**	**0.6x**

**Estimates are from Capital IQ and Stonegate Capital Partners (for SNOA)*
Source: Company reports, Stonegate Capital Partners

We also note that since 2008, companies in the dermatology space have been acquired at median EV/S multiple of 3.6x.

Exhibit 10: Precedent Transactions

		Price (1)	Revenue	Multiple
Acquired Companies	**Acquirer**			
Steifel Laboratories	Sinclair Pharmaceutical (LON: SPH)	$ 3,600.0	$ 1,000	3.6x
Medicis Pharmaceutical	Valeant Pharmaceuticals (TSX: VRX)	$ 2,600.0	$ 721	3.6x
Fougera Pharmaceutical	Sandox, Inc.	$ 1,525.0	$ 429	3.6x
PreCision Dermatology	Valeant Pharmaceuticals (TSX: VRX)	$ 500.0	$ 130	3.8x
Graceway Pharmaceuticals	Medicis Pharmaceutical	$ 455.0	$ 355	1.3x
Aqua Pharmaceuticals	Almiral, S.A. (CAT: ALM)	$ 402.0	$ 127	3.2x
SkinMedica	Allergan, Inc.	$ 350.0	$ 69	5.1x
Dow Pharmaceutical Sciences	Valeant Pharmaceuticals (TSX: VRX)	$ 285.0	$ 45	6.3x
Allergan	Actavis (NYSE: ACT)	$ 77,000.0	$ 7,238	10.6x
			Average	**4.6x**
			Median	**3.6x**
Sonoma Pharmaceuticals, Inc.				**0.6x**

(1) Closing price at acquisition

Source: Company reports, CapitalIQ, Stonegate Capital Partners

All figures in $M expect per share information

Following the sale of the Latin American business, we again note that Sonoma still reported approximately $8.6M in cash on hand at 12/31/17; therefore, cash value per share alone was approximately $1.82 as we consider the current share price of $4.22 on a company that had over 30% growth in revenues for fiscal 2016 and 2017, and over 40% growth for the most recent quarter y-o-y. Given this and the Company's current multiples vs. those of comparable companies in addition to the SNOA multiple when compared to precedent transactions in the dermatology space, we believe that Sonoma is significantly undervalued at current levels as a company well-positioned to continue capturing high growth in the US dermatology space.

2-YEAR TIMELINE

January 2018 – Three new United Arab Emirates regulatory approvals received with launch of the three related products expected in February 2018

December 2017 – Second FDA approval to add antimicrobial language to Levicyn™ gel products and dermal spray (first Nov. 2017)

October 2017 – Loyon® skin descaler commercialized in US, and approvals to market multiple hypochlorous acid-based derm products received in Brazil

September 2017 – MicrocynAH® animal healthcare products commercialized in Japan

June 2017 – SNOA announces two Singapore approvals for Microcyn® for treatment of atopic dermatitis and hypertrophic/keloid scars

April 2017 – Company receives two new United Arab Emirates regulatory approvals for Pediacyn® for atopic dermatitis and Epicyn® for scar management

March 2017 – Loyon® skin descaler receives FDA approval for the treatment of skin scaling related to dermatoses; Sonoma receives final $1.5M payment from sale of Latin America business

February 2017 – PetSmart, Inc. launched MicrocynAH® family of healthcare products with chain-wide availability; SNOA also announced positive results from SebuDerm™ study in treatment of mild to moderate facial and scalp seborrheic dermatitis

December 2016 – Management announced a corporate name change to Sonoma Pharmaceuticals, Inc. with new ticker SNOA

October 2016 – SNOA sold Latin American business to Invekra for $19.5M in cash and 3% annually on Latin American sales outside Mexico with $250K annual minimum

August 2016 – Company received approvals for the marketing (launch target of January 2017) of Microcyn® solution and hydrogel in Australia and New Zealand, and new post-dermal procedures product received US FDA approval with an estimated launch of March 2017; Company also launched Lasercyn™ into US markets

June 2016 - Company announced 1-for-5 reverse split effective 6/24/16

May 2016 – Ceramax™ Skin Barrier Cream launched in the US for atopic dermatitis and other dermatoses

April 2016 - Company announced FDA approval of Lasercyn™ Gel for use following laser procedures, microdermabrasions, and chemical peels; additionally, EU approval received for marketing of Sinudox™ as indicated for use in nasal irrigation

March 2016 - Sales and distribution agreement with Manna Pro Products, LLC announced, expanding the animal care products channel

January 2016 - CE Mark issued for MucoClyns™, a Microcyn®-based solution intended for emergencies

CORPORATE GOVERNANCE

Jim Schutz, J.D., Chief Executive Officer, President and Director - Jim Schutz has 20 years of experience in healthcare and was appointed CEO in February 2013. Mr. Schutz was formerly the general counsel of Jomed, Inc. until 2003 when he orchestrated the sale of Jomed to Abbott Laboratories (NYSE: ABT) and Volcano Therapeutics (NASDAQ: VOLC, now part of Royal Philips, NYSE: PHG). Mr. Schutz received a B.A. in economics from the University of California, San Diego and a J.D. from the University of San Francisco School of Law.

Robert Miller, Chief Financial and Operating Officer - Mr. Robert E. Miller has been the Chief Financial Officer of Sonoma since June 2004, and he serves as its Principal Accounting Officer. Mr. Miller has been Chief Operating Officer and Secretary of Sonoma since February 2013. He has over 20 years of experience as Chief Financial Officer for companies up to $650 million. Mr. Miller's early career was with Merrill Lynch and Blyth Eastman Dillion, Inc., where he served as Vice President of Investment Banking. Mr. Miller served as Chief Financial Officer for GAF Corporation, Penwest Ltd., Cerus, Ameron, and Bugle Boy, and Treasurer of Mead Corporation. Mr. Miller served as a Consultant to Sonoma from March 2003 to May 2004. Mr. Miller holds a B.A. in Economics from Stanford University and an M.B.A. in Corporate Finance and Accounting from the Columbia University Graduate School of Business.

Mark Umscheid, Chief Strategy and Marketing Officer – On January 31, 2017, Sonoma announced the appointment of Marc Umscheid as Chief Strategy and Marketing Officer. Previously, Mr. Umscheid worked at the Clorox Company where he most recently served as senior marketing director and business development team leader. As CSO/CMO at Sonoma, Mr. Umscheid will direct overall global strategy and marketing efforts while facilitating continued revenue growth across the Sonoma Pharmaceutical product portfolio, which includes dermatology, advanced wound care and animal healthcare products. Mr. Umscheid will report directly to Sonoma CEO Jim Schutz. Umscheid is a graduate of Cornell University, where he received both a BS in business management/finance and an MBA from the Johnson Graduate School of Management.

Robert Northey, Ph.D., Executive Vice President of Research and Development - Dr. Robert Northey, Ph.D. serves as Executive Vice President of Research and Development at Sonoma and served as its Vice President of Research and Development. Dr. Northey served as Director for Research and Development of Sonoma since July 2005. He served as a consultant to Sonoma from May 2001 to June 2005. From August 1998 to June 2005, he was an Assistant Professor in the Paper Science and Engineering Department at the University of Washington. He received a B.S. in wood and fiber science and a Ph.D. in wood chemistry, each from the University of Washington.

Board of Directors:

James Schutz – *Chief Executive Officer, President and Director*

Russell Harrison – *Independent Director*

John McLaughlin – *Lead Independent Director*

Sharon Surrey-Barbari – *Independent Director*

Jay Edward Birnbaum, Ph.D. – *Independent Director*

IMPORTANT DISCLOSURES AND DISCLAIMERS

The following disclosures are related to Stonegate Capital Partners (SCP) research reports.

ANALYST DISCLOSURES
I, Laura S. Engel, CPA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING, REFERRALS, AND FEES FOR SERVICE
SCP does not provide nor has it received compensation for investment banking services on the securities covered in this report. SCP does not expect to receive compensation for investment banking services on the securities covered in this report. SCP has a non-exclusive Advisory Services agreement to provide research coverage, retail and institutional awareness, and overall Investor Relations support and for which it is compensated $2,000 per month. Stonegate Capital Markets (SCM) is an affiliate of SCP and a member of FINRA/SIPC. SCM may seek to receive future compensation for investment banking or other business relationships with the covered companies mentioned in this report. In certain instances, SCP has contracted with SCM to produce research reports for its client companies.

POLICY DISCLOSURES
SCP Analysts are restricted from holding or trading securities in the issuers that they cover. SCP and SCM do not make a market in any security nor do they act as dealers in securities. Each SCP analyst has full discretion on the content and valuation discussion based on his or her own due diligence. Analysts are paid in part based on the overall profitability of SCP. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by SCP for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article. No employee of SCP serves on the Company's Board of Directors. Research Analyst and/or a member of the Analyst's household do not own shares of this security. Research Analyst and/or a member of the Analyst's household do not serve as an officer, director, or advisory board member of the Company. This security is eligible for sale in one or more states. This security is subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities. SCP or its affiliates do not beneficially own 1% or more of an equity security of the Company. SCP does not have other actual, material conflicts of interest in the securities of the Company.

ADDITIONAL INFORMATION
Please note that this report was originally prepared and issued by SCP for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of SCP should seek the advice of their independent financial advisor prior to making any investment decision based on this report or for any necessary explanation of its contents. The information contained herein is based on sources that we believe to be reliable, but is not necessarily complete and its accuracy cannot be guaranteed. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of SCP and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein. The firm and/or its employees and/or its individual shareholders and/or members of their families and/or its managed funds may have positions or warrants in the securities mentioned and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the firm from time to time in the open market or otherwise. While we endeavor to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. All opinions are subject to change without notice, and we do not undertake to advise you of any such changes. Reproduction or redistribution of this report without the expressed written consent of SCP is prohibited. Additional information on any securities mentioned is available on request.

RATING & RECOMMENDATION
SCP does not rate the securities covered in its research. SCP does not have, nor has previously had, a rating for any securities of the Company. SCP does not have a price target for any securities of the Company.

CONTACT INFORMATION

Sonoma Pharmaceuticals, Inc.
Robert Miller, CFO
1129 North McDowell Blvd.
Petaluma, CA 94954
Phone: 707-283-0550
www.sonomapharma.com

Investor Relations
Stonegate Capital Partners
8201 Preston Rd., #325
Dallas, TX 75225
Phone: 214-987-4121
www.stonegateinc.com